United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $529.59, for a total transaction of $5,031,105.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,455,279.67. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

Shares of UTHR stock opened at $527.00 on Friday. The stock has a market capitalization of $23.10 billion, a price-to-earnings ratio of 18.89, a PEG ratio of 1.91 and a beta of 0.84. The company’s fifty day simple moving average is $489.57 and its two-hundred day simple moving average is $466.41. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $548.12.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the company earned $6.19 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on UTHR shares. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $548.09.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in UTHR. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.